Abstracts - faqs.org

Abstracts

News, opinion and commentary

Search abstracts:
Abstracts » News, opinion and commentary

Struggling dot-com company gets opportunity for a second act

Article Abstract:

Terayon Communications Systems was locked out of the U.S. cable modem market until CableLabs decided the firm's technology should be part of the standards. The firm's stocks rose more than 50% on the day of that news. Its ratings went from 'hold' to 'buy' or 'strong buy.' CableLabs is a nonprofit research group funded by the cable industry. Terayon's technology is called S-CDMA, Synchronous Code Division Multiple Access.

Author: Berenson, Alex
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2001
Semiconductors and related devices, Semiconductor Devices, Semiconductor and Related Device Manufacturing, Telephone and telegraph apparatus, Modems, 301-1200 bps, Printed Circuit Assembly (Electronic Assembly) Manufacturing, Standards, Semiconductor industry, Management, Computer network equipment industry, Network hardware industry, Finance, Internet services, Cable modem, Cable modems, Technology development, Cable television, Securities, Company business management, Cable television/data services, Company financing, Cable Television Laboratories Inc., Terayon Communications Systems Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


At Vioxx Trial, a Discrepancy Appears to Undercut Merck's Defense

Article Abstract:

In a letter to physicians, in 2001, Merck and Company failed to report the actual number of patients having cardiovascular problems as a result of taking Vioxx.

Author: Berenson, Alex
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
Complications and side effects, Records and correspondence, Wrongful death, Evidence, Santanello, Nancy

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Jury Begins To Deliberate Vioxx Case

Article Abstract:

Pharmaceutical giant, Merck and Company Inc. are fighting their second lawsuit related to the safety of their pain medication Vioxx. The company did not alert doctors to the serious complications and side effects of the drug.

Author: Berenson, Alex
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
Health aspects, Conduct of court proceedings, Courtroom proceedings, Humeston, Frederick

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Company legal issue, Cases, Product defects and recalls, Pharmaceutical industry, Vioxx (Medication), Merck & Company Inc.
Similar abstracts:
  • Abstracts: Bell Canada to propose shared phone lines to cut costs for ISPs. Internet phone system cheaper, study says
  • Abstracts: Court allows Iridium creditors to sue Motorola for billions. More Losers in Funds Seek Equity in Court
  • Abstracts: With mine approval, Crystallex's value as target seen on rise. Environmentalists seek cruise rules
  • Abstracts: Gates sees decision as green light to `go forward.'(But line has been drawn.) Net rivals gird for latest battle
  • Abstracts: In pursuit of computing's Holy Grail: a make-or-break assault on Intel's chip dominance bears its first fruit
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.